https://hillmanv.com/awards2026-07-260.7 https://hillmanv.com/andrew-hillman-og.pngAwards & Service https://hillmanv.com/img/scottish-rite-for-children.pngScottish Rite for Children https://hillmanv.com/img/temple-emanu-el-dallas.pngTemple Emanu-El, Dallas, Texas https://hillmanv.com/img/parish-episcopal-building.jpegParish Episcopal School Dallas main building https://hillmanv.com/img/parish-episcopal-campus-map.jpegParish Episcopal School Dallas campus map https://hillmanv.com/img/lamplighter-hillman-innovation-lab.jpegLamplighter School Hillman Innovation Lab https://hillmanv.com/img/lamplighter-hillman-interior.jpegLamplighter School Hillman Innovation Lab interior https://hillmanv.com/coverage2026-07-260.7 https://hillmanv.com/exits2026-07-260.7 https://hillmanv.com/andrew-hillman-og.pngAndrew Hillman Strategic Exits https://hillmanv.com/faq2026-07-260.7 https://hillmanv.com/andrew-hillman-og.pngFrequently Asked Questions https://hillmanv.com/2026-07-261.0 https://hillmanv.com/andrew-hillman-og.pngHillman Ventures HV monogram with the Hillman Ventures wordmark https://hillmanv.com/img/andrew-hillman-speaking.jpegAndrew Hillman, principal.Andrew Jonathan Hillman, principal of Hillman Ventures, speaking https://hillmanv.com/img/andrew-hillman-30-years-innovation.jpegAndrew Hillman, Dallas.Andrew Hillman: driving 30 years of business innovation. https://hillmanv.com/img/andrew-hillman-ven-portrait.webpAndrew Hillman, Dallas.Andrew J. Hillman, principal of Hillman Ventures https://hillmanv.com/now2026-07-260.7 https://hillmanv.com/andrew-hillman-og.pngNow https://hillmanv.com/press2026-07-260.7 https://hillmanv.com/andrew-hillman-og.pngAndrew Hillman https://hillmanv.com/img/scottish-rite-for-children.pngScottish Rite for Children https://hillmanv.com/img/temple-emanu-el-dallas.pngTemple Emanu-El, Dallas, Texas https://hillmanv.com/publications2026-07-260.7 https://hillmanv.com/andrew-hillman-og.pngWriting & Publications https://hillmanv.com/img/last-part-standing-cover.jpgLast Part Standing book cover https://hillmanv.com/speaking2026-07-260.7 https://hillmanv.com/andrew-hillman-og.pngSpeaking & Talks https://hillmanv.com/stats2026-07-260.7 https://hillmanv.com/andrew-hillman-og.pngAndrew Hillman Track Record Statistics https://hillmanv.com/timeline2026-07-260.7 https://hillmanv.com/img/ajh-personal-logo.jpegCareer Timeline https://hillmanv.com/img/next-health-logo.jpegNext Health logo https://hillmanv.com/ventures2026-07-260.7 https://hillmanv.com/andrew-hillman-og.pngVentures & Companies https://hillmanv.com/img/next-health-logo.jpegNext Health logo https://hillmanv.com/img/pharma-holdings-us-logo.jpegPharma Holdings U.S. logo https://hillmanv.com/writing/351-vs-361-fda-exosome-pathway2026-07-260.7 https://andrew-hillman.com/img/ajh-personal-logo.jpegThe 351 vs 361 Decision That Kills Most Exosome Programs https://hillmanv.com/writing/dallas-quietly-becoming-best-place-build-biotech2026-07-260.7 https://andrew-hillman.com/img/ajh-personal-logo.jpegWhy Dallas Is Quietly Becoming the Right Place to Build FDA-Regulated Biotech https://hillmanv.com/writing/family-office-capital-fits-biotech-better2026-07-260.7 https://andrew-hillman.com/img/ajh-personal-logo.jpegWhy Family Office Capital Fits FDA-Regulated Biotech Better Than Venture Money https://hillmanv.com/writing/ftc-nextmed-telehealth-roadmap2026-07-260.7 https://andrew-hillman.com/img/ajh-personal-logo.jpegThe NextMed Settlement Is a Roadmap. Read It Before You Build the Next Telehealth Brand. https://hillmanv.com/writing2026-07-260.7 https://hillmanv.com/andrew-hillman-og.pngWriting https://hillmanv.com/writing/pattern-that-killed-five-biotech-programs2026-07-260.7 https://andrew-hillman.com/img/ajh-personal-logo.jpegThe Specific Pattern That Killed Five Biotech Programs I Personally Watched https://hillmanv.com/writing/six-compliance-patterns-federal-enforcement2026-07-260.7 https://andrew-hillman.com/img/ajh-personal-logo.jpegThe Six Documentation Patterns That Show Up Before Federal Healthcare Enforcement https://hillmanv.com/writing/thirty-years-operating-fda-regulated-healthcare2026-07-260.7 https://andrew-hillman.com/img/ajh-personal-logo.jpegWhat Thirty Years of Operating in FDA-Regulated Healthcare Actually Taught Me https://hillmanv.com/portfolio-letter-q2-20262026-07-260.7 https://hillmanv.com/insights/2026-07-260.8 https://hillmanv.com/img/og-card.jpgInsights https://hillmanv.com/insights/why-biotech-startups-fail/2026-07-260.7 https://hillmanv.com/img/og-card.jpgWhy Most Biotech Startups Fail https://hillmanv.com/insights/fda-approval-process-explained/2026-07-260.7 https://hillmanv.com/img/og-card.jpgFDA Approval Process: A Founder https://hillmanv.com/insights/manufacturing-moat-biotech/2026-07-260.7 https://hillmanv.com/img/og-card.jpgManufacturing: The Real Biotech Moat https://hillmanv.com/insights/how-to-invest-in-biotech/2026-07-260.7 https://hillmanv.com/img/og-card.jpgHow to Invest in Biotech Companies https://hillmanv.com/insights/biotech-investment-lifecycle/2026-07-260.7 https://hillmanv.com/img/og-card.jpgThe Biotech Investment Lifecycle, Explained https://hillmanv.com/insights/healthcare-venture-capital-explained/2026-07-260.7 https://hillmanv.com/img/og-card.jpgHealthcare Venture Capital Explained https://hillmanv.com/insights/what-makes-biotech-investable-2026/2026-07-260.7 https://hillmanv.com/img/og-card.jpgWhat Makes a Biotech Company Investable in 2026 https://hillmanv.com/insights/fda-strategy-biotech-valuation/2026-07-260.7 https://hillmanv.com/img/og-card.jpgWhy FDA Strategy Determines Biotech Valuation https://hillmanv.com/insights/ind-vs-nda-vs-bla/2026-07-260.7 https://hillmanv.com/img/og-card.jpgIND vs NDA vs BLA, Explained https://hillmanv.com/insights/common-fda-mistakes-biotech-startups/2026-07-260.7 https://hillmanv.com/img/og-card.jpgCommon FDA Mistakes That Kill Biotech Startups https://hillmanv.com/insights/regulatory-strategy-fundraising-exit-value/2026-07-260.7 https://hillmanv.com/img/og-card.jpgHow Regulatory Strategy Drives Biotech Fundraising https://hillmanv.com/insights/how-to-commercialize-biotech-innovation/2026-07-260.7 https://hillmanv.com/img/og-card.jpgHow to Commercialize a Biotech Innovation https://hillmanv.com/insights/from-lab-to-market-biotech-scaling/2026-07-260.7 https://hillmanv.com/img/og-card.jpgFrom Lab to Market: The Challenges of Biotech Scaling https://hillmanv.com/insights/role-of-reimbursement-healthcare-startups/2026-07-260.7 https://hillmanv.com/img/og-card.jpgThe Role of Reimbursement in Healthcare Startups https://hillmanv.com/insights/why-great-science-fails-without-commercialization/2026-07-260.7 https://hillmanv.com/img/og-card.jpgWhy Great Science Fails Without Commercialization https://hillmanv.com/insights/future-of-healthcare-investing/2026-07-260.7 https://hillmanv.com/img/og-card.jpgThe Future of Healthcare Investing https://hillmanv.com/insights/why-precision-medicine-will-dominate/2026-07-260.7 https://hillmanv.com/img/og-card.jpgWhy Precision Medicine Will Dominate the Next Decade https://hillmanv.com/insights/shift-from-treatment-to-prevention/2026-07-260.7 https://hillmanv.com/img/og-card.jpgThe Shift From Treatment to Prevention https://hillmanv.com/insights/why-investors-misprice-regulatory-risk/2026-07-260.7 https://hillmanv.com/img/og-card.jpgWhy Investors Misprice Regulatory Risk in Biotech https://hillmanv.com/insights/the-new-biotech-economy/2026-07-260.7 https://hillmanv.com/img/og-card.jpgThe New Biotech Economy, Explained https://hillmanv.com/insights/biotech-valuations-ignore-regulatory-reality/2026-07-260.7 https://hillmanv.com/img/og-card.jpgWhy Biotech Valuations Ignore Regulatory Reality https://hillmanv.com/insights/hidden-risk-healthcare-investors-miss/2026-07-260.7 https://hillmanv.com/img/og-card.jpgThe Hidden Risk Most Healthcare Investors Miss https://hillmanv.com/insights/drug-development-systems-problem/2026-07-260.7 https://hillmanv.com/img/og-card.jpgWhy Drug Development Is a Systems Problem https://hillmanv.com/insights/fda-approval-timelines-misconception/2026-07-260.7 https://hillmanv.com/img/og-card.jpgThe Biggest Misconception About FDA Approval Timelines https://hillmanv.com/glossary2026-07-260.7 https://hillmanv.com/privacy2026-08-090.3 https://hillmanv.com/terms2026-08-090.3 https://hillmanv.com/accessibility2026-08-090.3 https://hillmanv.com/disclaimer2026-08-090.3 https://hillmanv.com/right-to-try2026-08-090.3 https://hillmanv.com/sitemap2026-08-090.4